Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,109
  • Shares Outstanding, K 37,572
  • Annual Sales, $ 0 K
  • Annual Income, $ -138,430 K
  • EBIT $ -133 M
  • EBITDA $ -131 M
  • 60-Month Beta -0.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.87

Options Overview Details

View History
  • Implied Volatility 220.49% ( +43.59%)
  • Historical Volatility 120.48%
  • IV Percentile 85%
  • IV Rank 24.94%
  • IV High 747.02% on 04/14/25
  • IV Low 45.55% on 06/06/24
  • Put/Call Vol Ratio 3.97
  • Today's Volume 149
  • Volume Avg (30-Day) 340
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 10,489
  • Open Int (30-Day) 11,988

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.73
  • Number of Estimates 3
  • High Estimate -0.50
  • Low Estimate -0.91
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +29.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +7.97%
on 05/15/25
2.4100 -38.17%
on 04/25/25
-0.2000 (-11.83%)
since 04/17/25
3-Month
1.3800 +7.97%
on 05/15/25
3.7500 -60.27%
on 02/20/25
-2.0800 (-58.26%)
since 02/19/25
52-Week
1.3800 +7.97%
on 05/15/25
13.0700 -88.60%
on 10/09/24
-10.7500 (-87.83%)
since 05/17/24

Most Recent Stories

More News
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

BMEA : 1.4750 (-2.96%)
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

BMEA : 1.4750 (-2.96%)
IVEY PMI Reading Due Next Week in Canada

IVEY PMI Reading Due Next Week in Canada U.S. Monday Economic Lookahead Consumer credit ...

WDFC : 246.12 (+0.19%)
TLRY.TO : 0.68 (+9.68%)
JPM : 264.94 (-0.98%)
AGF-B.TO : 11.37 (-0.79%)
MAMA : 6.81 (-0.58%)
CCA.TO : 68.37 (-0.32%)
BYRN : 25.44 (+0.28%)
RPM : 115.36 (-0.57%)
DAL : 51.22 (+0.59%)
LEVI : 17.70 (+0.17%)
SMPL : 36.04 (-1.48%)
PLAY : 21.22 (-1.80%)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BMEA : 1.4750 (-2.96%)
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

BMEA : 1.4750 (-2.96%)
Biomea Fusion Announces Leadership Transition

BMEA : 1.4750 (-2.96%)
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

BMEA : 1.4750 (-2.96%)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BMEA : 1.4750 (-2.96%)
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

BMEA : 1.4750 (-2.96%)
Biomea Fusion to Become a Diabetes & Obesity Medicines Company

BMEA : 1.4750 (-2.96%)

Business Summary

Biomea Fusion Inc. is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion Inc. is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 1.6967
2nd Resistance Point 1.6133
1st Resistance Point 1.5667
Last Price 1.4750
1st Support Level 1.4367
2nd Support Level 1.3533
3rd Support Level 1.3067

See More

52-Week High 13.0700
Fibonacci 61.8% 8.6044
Fibonacci 50% 7.2250
Fibonacci 38.2% 5.8456
Last Price 1.4750
52-Week Low 1.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar